Holen Sie sich die Stockscreener-App
67.06
2.21%
1.5703
Schlusskurs vom Vortag:
$65.49
Offen:
$65.01
24-Stunden-Volumen:
419.34K
Relative Volume:
0.54
Marktkapitalisierung:
$3.05B
Einnahmen:
$1.32B
Nettoeinkommen (Verlust:
$175.44M
KGV:
18.43
EPS:
3.6395
Netto-Cashflow:
$308.08M
1W Leistung:
+17.74%
1M Leistung:
+11.69%
6M Leistung:
-17.11%
1J Leistung:
+1.33%
1-Tages-Spanne:
$64.50
$67.11
1-Wochen-Bereich:
$55.75
$67.01
52-Wochen-Spanne:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
67.06 | 2.98B | 1.32B | 175.44M | 308.08M | 3.6395 |
ABT
Abbott Laboratories
|
86.70 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.12 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.78 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.80 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.66 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Is It Time To Reassess Haemonetics (HAE) After The Recent Share Price Jump - simplywall.st
Medical Devices & SuppliesSpecialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE) - Yahoo Finance
Haemonetics (HAE) Upgraded to Buy by Bank of America, Target Pri - GuruFocus
HAE Upgraded by B of A Securities -- Price Target Raised to $80 - GuruFocus
Haemonetics (HAE) Upgraded to Buy by Bank of America, Shares Cli - GuruFocus
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends - Yahoo! Finance Canada
This Texas Instruments Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday - Benzinga
BofA upgrades Haemonetics stock rating on conservative guidance - Investing.com
HAE Stock Price, Quote & Chart | HAEMONETICS CORP/MASS (NYSE:HAE) - ChartMill
Is It Too Late to Buy Haemonetics Corp (HAE) After 4.0% Rally? G - GuruFocus
Does Haemonetics (HAE) Have Enduring Growth Potential? - Insider Monkey
Q3 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics Corp 2026 Annual Report: Business Overview, Market Segments, Products, and Competitive Landscape - Minichart
Haemonetics (NYSE: HAE) outlines segment shifts, major customers and risks - Stock Titan
Haemonetics (HAE) EVP and General Counsel receives 28,424 RSUs, 2,913 shares withheld for taxes - Stock Titan
[Form 4] HAEMONETICS CORP Insider Trading Activity - Stock Titan
Haemonetics (NYSE: HAE) CFO granted 29,312 RSUs with tax withholding - Stock Titan
Haemonetics (NYSE: HAE) VP granted 2,220 RSUs, 197 shares withheld for tax - Stock Titan
Haemonetics (HAE) EVP Roy Galvin granted RSUs as 879 shares withheld for taxes - Stock Titan
Haemonetics (HAE) SVP granted RSUs while shares withheld to cover taxes - Stock Titan
Haemonetics (HAE) CEO receives 78,344 RSUs and has shares withheld for taxes - Stock Titan
Does Haemonetics' (HAE) Buyback-Funded Loss Quarter Hint at Shifting Earnings Quality Priorities? - simplywall.st
Haemonetics (HAE) Valuation Check As Earnings Pressure And Options Volatility Raise Questions - simplywall.st
Haemonetics (HAE) Q4 2026 Earnings Transcript - AOL.com
Haemonetics Sees FY27 Revenue, Adjusted EPS Up 4%-7% >HAE - Moomoo
Haemonetics Corp (HAE) Shares Surge 5.5% -- What GF Score of 74 Tells Investors - GuruFocus
North Peak group files 13G/A, Haemonetics (NYSE: HAE) shows ≤5% ownership - Stock Titan
Is the Options Market Predicting a Spike in Haemonetics Stock? - Yahoo Finance
HAE Maintained by Barrington Research -- Price Target Lowered to $89 - GuruFocus
Haemonetics Corp at Bank of America Global Healthcare Conference Transcript - GuruFocus
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Cuts Target Price to $89 - 富途牛牛
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - Yahoo Finance
TradingKey - TradingKey
Why Haemonetics Stock Is Dropping So Sharply - TipRanks
Why Haemonetics (HAE) Is Down 9.5% After Mixed FY26 Results And FY27 Outlook Reset - simplywall.st
Haemonetics Q4 Earnings Call Highlights - sharewise.com
Haemonetics Corporation (NYSE:HAE) Q4 2026 Earnings Call Transcript - Insider Monkey
A Look At Haemonetics (HAE) Valuation After Q4 Loss And Sector-Wide Medical Device Sell Off - simplywall.st
Haemonetics Earnings Call Highlights Growth Amid Headwinds - TipRanks
HAE Maintained by JP Morgan -- Price Target Lowered to $62.00 - GuruFocus
J.P. Morgan Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $62 - 富途牛牛
Baird Maintains Haemonetics(HAE.US) With Buy Rating, Cuts Target Price to $67 - 富途牛牛
Haemonetics Corporation Q4 2026 Earnings Call Summary - Yahoo Finance
Haemonetics (HAE) Reports Q4 Fiscal 2026 Revenue Growth and Posi - GuruFocus
Needham Maintains Haemonetics(HAE.US) With Hold Rating - 富途牛牛
Haemonetics (HAE) One Off Loss And Margin Hit Challenge Bullish Earnings Narrative - simplywall.st
Earnings call transcript: Haemonetics Q4 2026 beats EPS forecast, stock surges By Investing.com - Investing.com South Africa
Haemonetics Q4 FY2026 slides: earnings beat caps transformation plan - Investing.com
Haemonetics Q4 FY2026 slides: earnings beat caps transformation plan By Investing.com - Investing.com UK
Earnings call transcript: Haemonetics Q4 2026 beats EPS forecast, stock surges - Investing.com Australia
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.32%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):